CALCA and migraine disorder: One thousand six hundred seventy-two patients were split randomly into groups of different dosages of galcanezumab and a placebo. 60.9% of the patients on 240 mg showed a >50% decrease in migraines. CGRP mAb was proven to decrease migraines and not have any detrimental side effects.